The Experts below are selected from a list of 70656 Experts worldwide ranked by ideXlab platform
Lyn M Duncan - One of the best experts on this subject based on the ideXlab platform.
-
marginal zone lymphoma low grade b cell lymphoma of mucosa associated lymphoid Tissue type of skin and Subcutaneous Tissue a study of 15 patients
The American Journal of Surgical Pathology, 1996Co-Authors: Elizabeth M Bailey, Judith A Ferry, Nancy L Harris, Martin C Mihm, Joseph O Jacobson, Lyn M DuncanAbstract:Extranodal low-grade B-cell lymphoma of mucosa-associated lymphoid Tissue (MALT) type occurs in the gastrointestinal tract, salivary gland, thyroid, orbit, lung, and breast. We report 15 patients with MALT-type lymphomas involving skin and Subcutaneous Tissue. All patients had tumors with histologic features of low-grade B-cell lymphoma of MALT type, including marginal zone cells (15 of 15 cases), plasmacytic differentiation (10 of 15 cases), Dutcher bodies (three of 15 cases), and reactive germinal centers (10 of 15 cases). All expressed pan B-cell antigens and monotypic immunoglobulin. Seven patients (five women, two men) aged 29 to 86 years (median, 53 years) had primary MALT-type lymphoma of skin (6) or Subcutaneous Tissue (1). One patient had persistent disease, and four patients had relapses involving skin, Subcutaneous Tissue, breast, orbit, and lymph node. At last follow-up (11-121 months; median, 36 months), one patient was alive with disease, and six patients had no evidence of disease. Three patients (two women, one man) aged 36 to 67 years (median, 57 years) had concurrent MALT-type lymphoma involving both Subcutaneous Tissue and extracutaneous sites at primary diagnosis, including lung, breast, orbit, lymph node, and bone marrow. One patient responded to treatment but relapsed with lymphoma of the skin and breast. The other two patients had persistent disease despite treatment. One patient died of disease at 25 months, and, at last follow-up (7 and 46 months), two patients were alive with disease. Five patients (four women and one man) aged 29 to 72 years (median, 63 years) had secondary skin or Subcutaneous involvement by MALT-type lymphoma with primary tumors of ocular adnexa (3) or parotid gland (2). All five patients had relapses, which involved skin or Subcutaneous Tissue, parotid gland, lacrimal gland, breast, and lymph node. At last follow-up (61-137 months), two patients were alive with disease and three were alive with no evidence of disease. Low-grade B-cell lymphomas of MALT type may arise in or secondarily involve the skin and Subcutaneous Tissue and have a tendency to affect middle-aged to older women. These tumors are characterized by multiple extranodal relapses and are associated with long patient survival. Patients with primary MALT-type lymphoma of skin or Subcutaneous Tissue without extracutaneous involvement at diagnosis were more likely to experience prolonged disease-free survival than patients with extracutaneous spread at presentation (p < 0.03).
-
marginal zone lymphoma low grade b cell lymphoma of mucosa associated lymphoid Tissue type of skin and Subcutaneous Tissue a study of 15 patients
The American Journal of Surgical Pathology, 1996Co-Authors: Elizabeth M Bailey, Judith A Ferry, Nancy L Harris, Martin C Mihm, Joseph O Jacobson, Lyn M DuncanAbstract:Extranodal low-grade B-cell lymphoma of mucosa-associated lymphoid Tissue (MALT) type occurs in the gastrointestinal tract, salivary gland, thyroid, orbit, lung, and breast. We report 15 patients with MALT-type lymphomas involving skin and Subcutaneous Tissue. All patients had tumors with histologic
Mikkel Tottrup - One of the best experts on this subject based on the ideXlab platform.
-
bone Subcutaneous Tissue and plasma pharmacokinetics of cefuroxime in total knee replacement patients a randomized controlled trial comparing continuous and short term infusion
Apmis, 2019Co-Authors: Mikkel Tottrup, Bo Martin Bibby, Tore Forsingdal Hardlei, Kurt Fuursted, Kjeld Soballe, Hanne Birkesorensen, Peter Riis Hansen, Mats BueAbstract:Cefuroxime is widely used as antibiotic prophylaxis for orthopaedic procedures. We evaluated bone, Subcutaneous Tissue (SCT) and plasma pharmacokinetics of cefuroxime in male patients undergoing total knee replacement (TKR) after both traditional short-term infusion (STI) and continuous infusion (CI). Eighteen male patients undergoing TKR were randomly assigned to STI or CI of 1.5 g of cefuroxime. Measurements were obtained in plasma, SCT, cancellous and cortical bone every 30 min for 8 h following surgery. For sampling in solid Tissues, microdialysis was applied. Population pharmacokinetic modelling was performed in order to estimate pharmacokinetic parameters, and to assess the probability of attaining cefuroxime concentrations above clinically relevant minimal inhibitory concentrations (MICs) for 65% and 90% of the 8 h dosing interval. Low SCT and cortical bone penetration were found in both the STI and the CI group, but the findings were only significant in the STI group. Irrespective of MIC, Tissue and target, CI leads to improved probability of attaining relevant pharmacokinetic targets compared with STI. For the Staphylococcus aureus MIC breakpoint (4 μg/mL), STI leads to inadequate probability of target attainment. CI of 1.5 g of cefuroxime leads to improved probability of attaining relevant pharmacokinetic targets in male TKR patients compared with traditional STI. These findings suggest that application of CI may improve antibiotic prophylaxis for male TKR patients.
-
continuous versus short term infusion of cefuroxime assessment of concept based on plasma Subcutaneous Tissue and bone pharmacokinetics in an animal model
Antimicrobial Agents and Chemotherapy, 2015Co-Authors: Mikkel Tottrup, Bo Martin Bibby, Tore Forsingdal Hardlei, Mats Bue, Sigrid Kerrnjespersen, Kurt Fuursted, Kjeld Soballe, Hanne BirkesorensenAbstract:The relatively short half-lives of most β-lactams suggest that continuous infusion of these time-dependent antimicrobials may be favorable compared to short-term infusion. Nevertheless, only limited solid-Tissue pharmacokinetic data are available to support this theory. In this study, we randomly assigned 12 pigs to receive cefuroxime as either a short-term or continuous infusion. Measurements of cefuroxime were obtained every 30 min in plasma, Subcutaneous Tissue, and bone. For the measurements in solid Tissues, microdialysis was applied. A two-compartment population model was fitted separately to the drug concentration data for the different Tissues using a nonlinear mixed-effects regression model. Estimates of the pharmacokinetic parameters and time with concentrations above the MIC were derived using Monte Carlo simulations. Except for Subcutaneous Tissue in the short-term infusion group, the Tissue penetration was incomplete for all Tissues. For short-term infusion, the Tissue penetration ratios were 0.97 (95% confidence interval [CI], 0.67 to 1.39), 0.61 (95% CI, 0.51 to 0.73), and 0.45 (95% CI, 0.36 to 0.56) for Subcutaneous Tissue, cancellous bone, and cortical bone, respectively. For continuous infusion, they were 0.53 (95% CI, 0.33 to 0.84), 0.38 (95% CI, 0.23 to 0.57), and 0.27 (95% CI, 0.13 to 0.48) for the same Tissues, respectively. The absolute areas under the concentration-time curve were also lower in the continuous infusion group. Nevertheless, a significantly longer time with concentrations above the MIC was found for continuous infusion up until MICs of 4, 2, 2, and 0.5 μg/ml for plasma and the same three Tissues mentioned above, respectively. For drugs with a short half-life, like cefuroxime, continuous infusion seems to be favorable compared to short-term infusion; however, incomplete Tissue penetration and high MIC strains may jeopardize the continuous infusion approach.
Elizabeth M Bailey - One of the best experts on this subject based on the ideXlab platform.
-
marginal zone lymphoma low grade b cell lymphoma of mucosa associated lymphoid Tissue type of skin and Subcutaneous Tissue a study of 15 patients
The American Journal of Surgical Pathology, 1996Co-Authors: Elizabeth M Bailey, Judith A Ferry, Nancy L Harris, Martin C Mihm, Joseph O Jacobson, Lyn M DuncanAbstract:Extranodal low-grade B-cell lymphoma of mucosa-associated lymphoid Tissue (MALT) type occurs in the gastrointestinal tract, salivary gland, thyroid, orbit, lung, and breast. We report 15 patients with MALT-type lymphomas involving skin and Subcutaneous Tissue. All patients had tumors with histologic features of low-grade B-cell lymphoma of MALT type, including marginal zone cells (15 of 15 cases), plasmacytic differentiation (10 of 15 cases), Dutcher bodies (three of 15 cases), and reactive germinal centers (10 of 15 cases). All expressed pan B-cell antigens and monotypic immunoglobulin. Seven patients (five women, two men) aged 29 to 86 years (median, 53 years) had primary MALT-type lymphoma of skin (6) or Subcutaneous Tissue (1). One patient had persistent disease, and four patients had relapses involving skin, Subcutaneous Tissue, breast, orbit, and lymph node. At last follow-up (11-121 months; median, 36 months), one patient was alive with disease, and six patients had no evidence of disease. Three patients (two women, one man) aged 36 to 67 years (median, 57 years) had concurrent MALT-type lymphoma involving both Subcutaneous Tissue and extracutaneous sites at primary diagnosis, including lung, breast, orbit, lymph node, and bone marrow. One patient responded to treatment but relapsed with lymphoma of the skin and breast. The other two patients had persistent disease despite treatment. One patient died of disease at 25 months, and, at last follow-up (7 and 46 months), two patients were alive with disease. Five patients (four women and one man) aged 29 to 72 years (median, 63 years) had secondary skin or Subcutaneous involvement by MALT-type lymphoma with primary tumors of ocular adnexa (3) or parotid gland (2). All five patients had relapses, which involved skin or Subcutaneous Tissue, parotid gland, lacrimal gland, breast, and lymph node. At last follow-up (61-137 months), two patients were alive with disease and three were alive with no evidence of disease. Low-grade B-cell lymphomas of MALT type may arise in or secondarily involve the skin and Subcutaneous Tissue and have a tendency to affect middle-aged to older women. These tumors are characterized by multiple extranodal relapses and are associated with long patient survival. Patients with primary MALT-type lymphoma of skin or Subcutaneous Tissue without extracutaneous involvement at diagnosis were more likely to experience prolonged disease-free survival than patients with extracutaneous spread at presentation (p < 0.03).
-
marginal zone lymphoma low grade b cell lymphoma of mucosa associated lymphoid Tissue type of skin and Subcutaneous Tissue a study of 15 patients
The American Journal of Surgical Pathology, 1996Co-Authors: Elizabeth M Bailey, Judith A Ferry, Nancy L Harris, Martin C Mihm, Joseph O Jacobson, Lyn M DuncanAbstract:Extranodal low-grade B-cell lymphoma of mucosa-associated lymphoid Tissue (MALT) type occurs in the gastrointestinal tract, salivary gland, thyroid, orbit, lung, and breast. We report 15 patients with MALT-type lymphomas involving skin and Subcutaneous Tissue. All patients had tumors with histologic
V. Poitout - One of the best experts on this subject based on the ideXlab platform.
-
a glucose monitoring system for on line estimation in man of blood glucose concentration using a miniaturized glucose sensor implanted in the Subcutaneous Tissue and a wearable control unit
Diabetologia, 1993Co-Authors: V. Poitout, G Reach, Y. Zhang, G. S. Wilson, D Moattisirat, F Lemonnier, J C KleinAbstract:We have developed a miniaturized glucose sensor which has been shown previously to function adequately when implanted in the Subcutaneous Tissue of rats and dogs. Following a glucose load, the sensor output increases, making it possible to calculate a sensitivity coefficient to glucose in vivo, and an extrapolated background current in the absence of glucose. These parameters are used for estimating at any time the apparent Subcutaneous glucose concentration from the current. In the previous studies, this calibration was performed a posteriori, on the basis of the retrospective analysis of the changes in blood glucose and in the current generated by the sensor. However, for clinical application of the system, an on line estimation of glucose concentration would be necessary. Thus, this study was undertaken in order to assess the possibility of calibrating the sensor in real time, using a novel calibration procedure and a monitoring unit which was specifically designed for this purpose. This electronic device is able to measure, to filter and to store the current. During an oral glucose challenge, when a stable current is reached, it is possible to feed the unit with two different values of blood glucose and their corresponding times. The unit calculates the in vivo parameters, transforms every single value of current into an estimation of the glucose concentration, and then displays this estimation. In this study, 11 sensors were investigated of which two did not respond to glucose. In the other nine trials, the volunteers were asked to record every 30 s what appeared on the display during the secondary decrease in blood glucose. The results were analysed by comparing these readings (approximately 220 measurements per trial) to the changes in plasma glucose, measured every 15 min. The Error Grid Analysis indicated that 84.1±3.6% of the measurements were in zone A (accurate) and 15±3.6% were in zone B (acceptable). Considering each individual trial, the differences between the displayed value and the concomitant plasma glucose concentration ranged between −1.7 and 0.69 mmol/l. These excellent results were due to the absence of any significant lag between the changes in plasma glucose concentration and the changes in the result on the display. We conclude that this glucose monitoring system, based on Subcutaneous sensing of glucose, is able to provide a direct on line estimation of blood glucose concentration.
-
Towards continuous glucose monitoring: in vivo evaluation of a miniaturized glucose sensor implanted for several days in rat Subcutaneous Tissue
Diabetologia, 1992Co-Authors: D. Moatti-sirat, G Reach, F. Capron, V. Poitout, D. S. Bindra, Y. Zhang, G. S. Wilson, D. R. ThévenotAbstract:A miniaturized amperometric, enzymatic, glucose sensor (outer diameter 0.45 mm) was evaluated after implantation in the Subcutaneous Tissue of normal rats. A simple experimental procedure was designed for the long-term assessment of the sensor's function which was performed by recording the current during an intraperitoneal glucose load. The sensor was calibrated by accounting for the increase in the current during the concomitant increase in plasma glucose concentration, determined in blood sampled at the tail vein. This made it possible to estimate the glucose concentration in Subcutaneous Tissue. During the glucose load, the change in Subcutaneous glucose concentration followed that in blood with a lag time consistently shorter than 5 min. The estimations of Subcutaneous glucose concentration during these tests were compared to the concomitant plasma glucose concentrations by using a grid analysis. Three days after implantation ( n =6 experiments), 79 estimations were considered accurate, except for five which were in the acceptable zone. Ten days after implantation ( n =5 experiments), 101 estimations were accurate, except for one value, which was still acceptable. The sensitivity was around 0.5 nA mmol^−1·l^−1 on day 3 and day 10. A longitudinal study on seven sensors tested on different days demonstrated a relative stability of the sensor's sensitivity. Finally, histological examination of the zone around the implantation site revealed a fibrotic reaction containing neocapillaries, which could explain the fast response of the sensor to glucose observed in vivo, even on day 10. We conclude that this miniaturized glucose sensor, whose size makes it easily implanted, works for at least ten days after implantation into rat Subcutaneous Tissue.
Hanne Birkesorensen - One of the best experts on this subject based on the ideXlab platform.
-
bone Subcutaneous Tissue and plasma pharmacokinetics of cefuroxime in total knee replacement patients a randomized controlled trial comparing continuous and short term infusion
Apmis, 2019Co-Authors: Mikkel Tottrup, Bo Martin Bibby, Tore Forsingdal Hardlei, Kurt Fuursted, Kjeld Soballe, Hanne Birkesorensen, Peter Riis Hansen, Mats BueAbstract:Cefuroxime is widely used as antibiotic prophylaxis for orthopaedic procedures. We evaluated bone, Subcutaneous Tissue (SCT) and plasma pharmacokinetics of cefuroxime in male patients undergoing total knee replacement (TKR) after both traditional short-term infusion (STI) and continuous infusion (CI). Eighteen male patients undergoing TKR were randomly assigned to STI or CI of 1.5 g of cefuroxime. Measurements were obtained in plasma, SCT, cancellous and cortical bone every 30 min for 8 h following surgery. For sampling in solid Tissues, microdialysis was applied. Population pharmacokinetic modelling was performed in order to estimate pharmacokinetic parameters, and to assess the probability of attaining cefuroxime concentrations above clinically relevant minimal inhibitory concentrations (MICs) for 65% and 90% of the 8 h dosing interval. Low SCT and cortical bone penetration were found in both the STI and the CI group, but the findings were only significant in the STI group. Irrespective of MIC, Tissue and target, CI leads to improved probability of attaining relevant pharmacokinetic targets compared with STI. For the Staphylococcus aureus MIC breakpoint (4 μg/mL), STI leads to inadequate probability of target attainment. CI of 1.5 g of cefuroxime leads to improved probability of attaining relevant pharmacokinetic targets in male TKR patients compared with traditional STI. These findings suggest that application of CI may improve antibiotic prophylaxis for male TKR patients.
-
continuous versus short term infusion of cefuroxime assessment of concept based on plasma Subcutaneous Tissue and bone pharmacokinetics in an animal model
Antimicrobial Agents and Chemotherapy, 2015Co-Authors: Mikkel Tottrup, Bo Martin Bibby, Tore Forsingdal Hardlei, Mats Bue, Sigrid Kerrnjespersen, Kurt Fuursted, Kjeld Soballe, Hanne BirkesorensenAbstract:The relatively short half-lives of most β-lactams suggest that continuous infusion of these time-dependent antimicrobials may be favorable compared to short-term infusion. Nevertheless, only limited solid-Tissue pharmacokinetic data are available to support this theory. In this study, we randomly assigned 12 pigs to receive cefuroxime as either a short-term or continuous infusion. Measurements of cefuroxime were obtained every 30 min in plasma, Subcutaneous Tissue, and bone. For the measurements in solid Tissues, microdialysis was applied. A two-compartment population model was fitted separately to the drug concentration data for the different Tissues using a nonlinear mixed-effects regression model. Estimates of the pharmacokinetic parameters and time with concentrations above the MIC were derived using Monte Carlo simulations. Except for Subcutaneous Tissue in the short-term infusion group, the Tissue penetration was incomplete for all Tissues. For short-term infusion, the Tissue penetration ratios were 0.97 (95% confidence interval [CI], 0.67 to 1.39), 0.61 (95% CI, 0.51 to 0.73), and 0.45 (95% CI, 0.36 to 0.56) for Subcutaneous Tissue, cancellous bone, and cortical bone, respectively. For continuous infusion, they were 0.53 (95% CI, 0.33 to 0.84), 0.38 (95% CI, 0.23 to 0.57), and 0.27 (95% CI, 0.13 to 0.48) for the same Tissues, respectively. The absolute areas under the concentration-time curve were also lower in the continuous infusion group. Nevertheless, a significantly longer time with concentrations above the MIC was found for continuous infusion up until MICs of 4, 2, 2, and 0.5 μg/ml for plasma and the same three Tissues mentioned above, respectively. For drugs with a short half-life, like cefuroxime, continuous infusion seems to be favorable compared to short-term infusion; however, incomplete Tissue penetration and high MIC strains may jeopardize the continuous infusion approach.
